| Literature DB >> 32125935 |
Fouzia Radouani1, Lyndon Zass2, Yosr Hamdi3, Jorge da Rocha4, Reem Sallam5, Sonia Abdelhak3, Samah Ahmed6,7, Maryame Azzouzi1, Ichrak Benamri1,8, Alia Benkahla9, Balkiss Bouhaouala-Zahar10, Melek Chaouch9, Haifa Jmel3, Rym Kefi3, Ayoub Ksouri9,10, Judit Kumuthini11, Phumlani Masilela2, Collen Masimirembwa4,12, Houcemeddine Othman4, Sumir Panji2, Lilia Romdhane3,13, Chaimae Samtal14,15,16, Rania Sibira6,17, Kais Ghedira9, Faisal Fadlelmola6, Samar Kamal Kassim5, Nicola Mulder2.
Abstract
Effective interventions and treatments for complex diseases have been implemented globally, however, coverage in Africa has been comparatively lower due to lack of capacity, clinical applicability and knowledge on the genetic contribution to disease and treatment. Currently, there is a scarcity of genetic data on African populations, which have enormous genetic diversity. Pharmacogenomics studies have the potential to revolutionise treatment of diseases, therefore, African populations are likely to benefit from these approaches to identify likely responders, reduce adverse side effects and optimise drug dosing. This review discusses clinical pharmacogenetics studies conducted in African populations, focusing on studies that examined drug response in complex diseases relevant to healthcare. Several pharmacogenetics associations have emerged from African studies, as have gaps in knowledge.Entities:
Keywords: Africa; communicable diseases; genetic variation; noncommunicable diseases; pharmacogenetics; pharmacogenomics; precision medicine
Mesh：
Year: 2020 PMID： 32125935 DOI： 10.2217/pme-2019-0110
Source DB: PubMed Journal: Per Med ISSN： 1741-0541 Impact factor: 2.512